- LOTTE BIOLOGICS has entered a late-stage to commercial contract manufacturing partnership with a U.S.-based biopharmaceutical company.
- The agreement covers a Phase 3 programme and extends to mid-2030, marking the company’s third major partnership in 2025.
LOTTE BIOLOGICS has announced a late-stage to commercial contract manufacturing partnership with a U.S.-based global biopharmaceutical company. The agreement spans a Phase 3 programme advancing into multiple new indications and extends to commercial supply, subject to regulatory approval.
The company confirmed that the client’s name will remain undisclosed due to confidentiality obligations. The contract is set to run until the middle of 2030, reinforcing LOTTE BIOLOGICS’ role as a CDMO partner for advanced biopharmaceutical programmes.
This is the third major partnership secured by LOTTE BIOLOGICS in 2025. The company stated the deal highlights its U.S. manufacturing presence and aligns with the industry trend of reshoring and supply chain realignment in biomanufacturing.
LOTTE BIOLOGICS operates dual sites in Syracuse, New York, and Songdo, Korea, under a unified quality system. The company noted that these facilities enable it to provide proximity to key U.S. biopharma hubs, reliable supply, and flexible responses to changing demand.
A company representative said: “This late-stage to commercial partnership demonstrates strong client confidence in our global network and technical expertise. LOTTE is proud to support our partner’s indication expansion strategy and to help accelerate the availability of innovative therapies for patients worldwide.”
